Re­silience forges JV with MD An­der­son, ready­ing new cell ther­a­pies for can­cer

The Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter and con­tract bi­o­log­ic man­u­fac­tur­er Re­silience are crack­ing open a new part­ner­ship, seek­ing to ac­cel­er­ate the de­vel­op­ment and man­u­fac­tur­ing of cell ther­a­pies for can­cer pa­tients.

The so-called Cell Ther­a­py Man­u­fac­tur­ing Cen­ter will be based in a 60,000-square-foot fa­cil­i­ty in down­town Hous­ton. With a team of 70 em­ploy­ees, the cen­ter will fo­cus on process and an­a­lyt­i­cal de­vel­op­ment as well as ear­ly-phase and clin­i­cal-stage GMP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER